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Abstract
Background: While the most common pharmacological treatments for autoimmune renal pathologies are well
studied, herbal remedies are often overlooked. In this study, the effect of the herbal treatment Canephron® N (CAN)
in a rat model of active Heymann’s autoimmune glomerulonephritis (AIG) was investigated.
Methods: Forty BDIX male conventional rats and six female rats were divided into the following groups: healthy
animals, AIG, AIG treated with CAN, AIG treated with prednisolone, AIG treated with prednisolone and CAN.
Results: Prednisolone or CAN monotherapy comprises various positive pharmacological effects.
Rats receiving prednisolone showed moderate increase in CD4+ lymphocyte count, increase in CD8+ cytotoxic
lymphocyte count but incomplete normalization of CD4+/CD8+ lymphocyte ratio. It reduced the total count of
lymphocytes. Concentration of immune complexes and cryoglobulin level decreased considerably. Prednisolone
monotherapy ensured moderate reduction in nephrotic syndrome parameters.
CAN monotherapy did not affect immunological parameters and CD4+/CD8+ subpopulation ratio but reduced the
level of immune complexes significantly compared to AIG. The main nephroprotective effects of the drug were
normalization of diuresis and glomerular filtration rate. Significant reduction of leukocyturia was observed compared
to AIG group.
The most positive effects were observed in the combined Prednisolone + CAN group. Along with positive immunological
shifts in cell-bound and humoral links of immunity (prednisolone effects), renal function improved significantly:
proteinuria decreased, blood creatinine and urea decreased, AOPP and PCO levels also decreased (combined
effects of CAN). Qualitative differences suggest synergistic effects of complex therapy with glucocorticoid
immunosuppressor and the herbal medical drug.
Conclusions: The AIG model used in this study corresponds to human membranous glomerulonephritis in
terms of clinical morphology. Prednisolone monotherapy demonstrated adequate efficacy regarding immune
and metabolic components of renal disease.
The herbal monotherapy was shown to partially normalize urodynamics.
Combining CAN with the immunosuppressant prednisolone promotes more positive pharmacodynamic effects
on the immune and renal systems of rats.
The combined treatment may be useful in clinical nephrology practice including patients with kidney
autoimmune diseases and should be investigated further.
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Background
Preclinical and clinical nephrological studies focus on
three subjects: 1) improvement of renal failure diagnos-
tics [1, 2], 2) development of effective dialysis devices
and detoxification regimens [3], 3) search for novel med-
ical products for prevention and conservative treatment
of renal pathologies of various geneses [4].
Autoimmune renal pathology, both in animal models
and in humans, is associated with autoantibody-induced
destruction of nephron structures, deposition of immune
complexes, and migration of leukocytes to renal tissues
[5, 6]. Currently, the most common pharmacological
treatment to limit production of autoantibodies by Т-
helper-dependent autoreactive clones of В-lymphocytes
are immunodepressant drugs such as glucocorticoster-
oids (prednisolone, methylprednisolone), cytostatic drugs
(cyclophosphamide, chlorambucil), lymphocyte inosine
monophosphate dehydrogenase inhibitors (mycopheno-
late mofetil), inhibitors of calcium-dependent Т-cellular
signal transduction pathways (cyclosporine A, tacroli-
mus), suppressors of transcription of discrete group of
lymphokine gens, monoclonal antibodies, etc. Basic therapy
of autoimmune renal pathology includes the immunode-
pressants prednisolone, methylprednisolone, azathioprine,
cyclophosphamide, mycophenolate mofetil, cyclosporine А
and tacrolimus [7]. The treatment also includes anticoagu-
lants of the heparin group, angioprotectors [8], and herbal
medicinal products [9].
Herbal medicinal products in the treatment of this path-
ology are often considered last. Significant experience with
phytotherapy in renal and urinary diseases has been accu-
mulated over the years [4, 9, 10]. However, the evidentiary
basis, preclinical as well as clinical, of treating renal dis-
eases with phytotherapy remains still insufficient.
The herbal medicinal product Canephron N (CAN) pro-
duced by Bionorica SE combines three herbal components:
rosemary, lovage and centaury [11]. Pharmacological ef-
fects of CAN consist of anti-inflammatory, diuretic and
nephroprotective effects [12]. The main advantages of this
drug are the availability on the pharmaceutical market,
high efficacy in various renal and urinary pathologies,
safety and the possibility to use it in children and during
pregnancy. Safety and efficacy of CAN has been indicated
in pregnant women with late gestational toxicosis [13, 14].
The main studies, both clinical [15, 16] and preclinical
[17], prove efficacy of the drug in tubular pathology, such
as pyelonephritis and tubulointerstitial nephritis, as part of
combination therapy with antibacterial drugs (pefloxacin,
amoxiclav, roxithromycin) [18].
The aim of this study was to investigate the nephropro-
tective effects of CAN in complex pharmacotherapy in a
rat model of active Heymann’s autoimmune glomerulo-
nephritis (AIG). The study comprised the following groups:
1) healthy animals, 2) animals with AIG, 3) animals with
AIG treated with CAN (for 60 days), 4) animals with AIG
treated with the standard immunodepressant prednisolone
(for 60 days), and 5) animals with AIG treated with pred-
nisolone in combination with CAN (for 60 days). Evalu-
ation of pharmacological effect of the treatments was
performed using a series of laboratory tests recommended
for preclinical studies [19].
Methods
Animals
Work with the laboratory animals was in accordance with
the Guide for the Care and Use of Laboratory Animals
(USA, National Academy Press, Washington, D.C., 1996);
the Guide for the Care and Use of Laboratory Animals
(FELASA, 2010); Laboratory Animals (guidelines, Russian
Academy of Medical Sciences, Moscow, 2003) [20]. Exper-
iments were carried out with 40 BDIX male conventional
rats and 6 female rats [21] weighing 200–220 g pur-
chased from the Pavlov Institute of Physiology Russian
Academy of Sciences (Saint Petersburg, Russia). The
experimental protocol followed in this study was fully
approved by the Bioethics Committee Animal Care of
Institute of Toxicology.
Modeling of autoimmune glomerulonephritis (AIG)
To induce active Heymann’s glomerulonephritis, mater-
nal kidneys were isolated and homogenized, freed from
connective tissue and mixed with complete Freund’s
adjuvant (1:1) [22–24]. Thus maternal renal antigen con-
taining glycoprotein gp330 was obtained. At the age of
3 months rats of the f 1 generation were immunized by
two intraperitoneal administration of maternal renal
antigen (10 mg/200 g body weight) with a 14-day inter-
val. 28 days after the second immunization severity of
proteinuria was assessed (proteinuria in experimental
rats was at least 0.5 g/mmol creatinine/day) and rats
were divided into the following groups: healthy animals
not receiving immunization (Healthy n = 8), pathology
control (AIG, n = 8), prednisolone therapy (Prednisolone,
n = 8), CAN treatment (CAN, n = 8), prednisolone +
CAN treatment (Prednisolone + CAN, n = 8). Prednisol-
one was administered at 10 mg/kg/day, CAN oral drops
at 3.0 ml/kg/day [25]. Drug administration was per-
formed via nontraumatic gavage (p.o.) once daily for
60 days. 60 days after end of treatment, 24-hour urine
was collected from rats, and subsequently animals were
euthanized under anesthesia (zolazepam + tiletamine 1:1,
20 mg/kg) via instantaneous decapitation with blood
sampling for biochemical and immunological tests.
Parameters and tests
Twenty-four-hour urine volume was determined at the
end of experiment (day 60) by placing all rats for 24 hours
into metabolic cages (Tekniplast Gazzada, Italy) with free
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access to water (100 ml per each rat) without food. The
main markers of renal pathology (nephrotic syndrome)
were protein and erythrocyte levels in the urine.
Urine was analyzed using Aution Sticks 10EA test
strips on the AutionEleven АЕ-4020 (Arkray Factory,
Inc. (Japan)). Collected urine samples were analyzed
for count of erythrocytes, leukocytes, casts (supravital
staining using Sternheimer-Malbin method with micros-
copy in × 100 and × 400 magnification) [26, 27], protein
level (using pyrogallol red binding method at 600 nm) and
creatinine level (using Jaffe pseudokinetic reaction at
505 nm) [28]. Proteinuria in 24-hour urine was calculated
as g of protein per mmol of creatinine. Ready-to-use kits
for clinical chemistry manufactured by Abris + and Olvex
Diagnosticum (Russia) were used. Glomerular filtration
rate (GFR ml/min) was calculated using the equation
described by Methods in renal toxicology [29].
The blood was sampled into tubes with the anticoagu-
lant lithium heparin for immunological tests and into
clot activator tubes for biochemical tests (Vacuette).
Lymphocyte immunophenotyping
To evaluate count of CD4+ and CD8+ Т-lymphocytes,
murine monoclonal antibodies were used: PE labeled
anti-rat CD45, FITC labeled anti-rat CD3, APC labeled
anti-rat CD4, PerCP labeled anti-rat CD8a (BD Pharmin-
gen). 10 μl of antibody mixture were added to 50 μl of
blood and incubated for 30 min at room temperature.
Then 450 μl of 1 % BD FACSC™ Lysing Solution (BD,
USA) was added and incubated for 30 min. Cytometry
was carried out on flow cytofluorimeter BD FACSCalibur™
(BD Biosciences, USA) using CellQuestPrO universal soft-
ware [30]. At least 10 thousand cells were measured in
each sample.
Level of immune complexes (CIC) was defined using
turbidimetry in the presence of 3.5 % PEG-6000 in bor-
ate buffer at 450 nm [28, 31]. Cryoglobulin level was
determined after a 7-day serum incubation at +4 °C in
the presence of sodium azide, cryoprecipitate centrifuga-
tion, precipitate dissolved in 0.1 M sodium hydroxide
and spectrophotometry at 260 and 280 nm [31].
Serum level of renal damage biomarkers, i.e. urea
(blood urea nitrogen, BUN) and creatinine, was deter-
mined using a UV-kinetic method, and cholesterol at
500 nm by means of Randox Laboratories Ltd. (UK) kits
[28]. The level of advanced oxidation protein products
(AOPP) as a marker of chronic renal disease was
assessed at 340 nm using the Witko-Sarsat method [32],
carbonyl protein (PCO) binding to 2,4-dinitrophenylhy-
drazine at 370 nm [33]. Measurements were performed
using Synergy2 (BioTek Instruments, Inc., USA) micro-
plate reader. Correctness of measurements was ensured
using a control serum (Calibration sera level 1–3) by
Randox Laboratories Ltd. (UK) and urine materials
(Liquichek urinalysis level 1–2) by Bio-Rad (USA).
Statistical tests were performed using Statistica 8.0 Soft-
ware for Windows. The nonparametric Kruskall-Wallis
test and Mann–Whitney U test were used. Data are
presented as mean ± standard error of the mean (SEM).
Significance of differences was assessed at p ≤ 0.05 [34].
Results and discussion
Animals with AIG showed immunopathological shifts
characteristic for the autoimmune pathology: statistically
significant reduction of blood CD8+ Т-cells, of CD4+
Т-helper cells and increase of immune-regulatory
index (p ≤ 0.05). CD4+ T cells play a critical role in
the induction of Heymann’s nephritis. Concentration
Fig. 1 Evaluation of monotherapy and combination of prednisolone with CAN on the circulating immune complexes level (Mean±SEM) in a rat
model of active Heymann autoimmune glomerulonephritis: 1 – Healthy; 2 – AIG; 3 – AIG + Prednisolone; 4 – AIG + CAN; 5 – AIG + Prednisolone
+ CAN; n=8 in each group. Scatter dot plot. P value < 0,05
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of serum circulating immune complexes (CIC) increased
significantly (approximately 25-fold), and the cryoglobulin
level was increased 5.4-fold when compared to healthy
rats (Figs. 1 and 2).
Renal inflammation was indicated by enhanced protein-
uria, leukocyte- and hematuria, and the presence of
erythrocytic and waxy sediments (casts) in the urine of
the rats.
Total blood cholesterol, creatinine and urea increased
significantly (nephrotic syndrome). The AIG model was
also characterized by the accumulation of advanced oxi-
dation protein products (AOPP) and carbonyl protein
groups in blood, thus confirming the development of
chronic renal pathology in rats.
The effects of the experimental therapy on immuno-
logical parameters are presented in Table 1, biochemical
blood parameters in Table 2, and parameters of renal
function in Table 3.
Prednisolone or CAN monotherapy comprises various
positive pharmacological effects. Rats receiving prednis-
olone showed moderate increase in CD4+ lymphocyte
count up to the normal values, increase in CD8+ cyto-
toxic lymphocyte count but incomplete normalization of
CD4+/CD8+ lymphocyte ratio. However, prednisolone
reduced the total count of lymphocytes. Concentration
of immune complexes and cryoglobulin level decreased
considerably. Prednisolone monotherapy ensured moder-
ate reduction in nephrotic syndrome parameters – urea
and creatinine, total cholesterol and AOPP as well as
PCO, primarily albumin. Partial normalization of glom-
erular filtration rate took place along with reduced pro-
teinuria, erythrocyte- and leukocyturia; count of waxy and
red blood cell casts in urine also reduced significantly.
CAN monotherapy did not affect immunological pa-
rameters and CD4+/CD8+ subpopulation ratio but re-
duced the level of immune complexes significantly
compared to AIG. Biochemically, the drug produced
moderate positive effect on creatinine level only. The
main targets of nephroprotective effect of the drug were
the kidneys, i.e. normalization of diuresis and glomerular
filtration rate, probably due to creatinine elimination via
tubular secretion. Significant reduction of leukocyturia
Fig. 2 Evaluation of monotherapy and combination of prednisolone with CAN on the serum cryoglobulin level (Mean±SEM) in a rat model of
active Heymann autoimmune glomerulonephritis: 1 – Healthy; 2 – AIG; 3 – AIG + Prednisolone; 4 – AIG + CAN; 5 – AIG + Prednisolone + CAN;
n=8 in each group. Scatter dot plot. P value < 0,05
Table 1 Effect of therapy with prednisolone, CAN and their combination on the main immunological markers of autoimmune renal
pathology (mean ± SEM, n = 8 in each group)
Groups of animals Study parameters
CD3+, ×109/L CD4 + CD3+, % CD8 + CD3+, % Immune-regulatory index (CD4+/CD8+)
Healthy 5,7 ± 0,1 55,2 ± 0,9 44,1 ± 1,1 1,26 ± 0,04
AIG 5,5 ± 0,1 51,0 ± 1,6* 25,6 ± 1,3* 2,01 ± 0,07*
AIG + Prednisolone 4,9 ± 0,1 */† 52,1 ± 1,1 30,2 ± 1,3*/† 1,74 ± 0,07*/†
AIG + CAN 5,6 ± 0,1# 51,9 ± 1,2 26,2 ± 1,4* 2,00 ± 0,09*
AIG + Prednisolone + CAN 5,1 ± 0,1*/† 54,2 ± 0,7 34,5 ± 0,6*/†/# 1,58 ± 0,04*/†
* -differences are significant vs. healthy rats, р ≤ 0,05
† −differences are significant vs. AIG group, р ≤ 0,05
# -differences are significant vs. Prednisolone group, p ≤ 0,05
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was observed compared to AIG group which, however,
did not exceed prednisolone monotherapy. This could
be explained by anti-inflammatory effects of the drug.
Antioxidant effects were supported by the tendency for
blood AOPP and PCO reduction in CAN treatment.
The most positive effects were observed in the com-
bined Prednisolone + CAN group. Along with positive
immunological shifts in cell-bound and humoral links of
immunity (prednisolone effects), renal function improved
significantly: proteinuria decreased, blood creatinine and
urea decreased due to GFR increase, AOPP and PCO
levels also decreased (combined effects of CAN). Qualita-
tive differences suggesting synergistic effects of complex
therapy with glucocorticoid immunosuppressor and the
herbal medical drug included significant differences in
terms of CD8+ lymphocytes (р = 0.024), cryoglobulins
(р = 0.021), advanced oxidation protein products (р =
0.016), carbonyl groups (р = 0.015), erythrocyturia (р =
0.011) and leukocyturia (р = 0.001) vs. group of animals
receiving prednisolone monotherapy.
Conclusions
The AIG model used in this study corresponds to human
membranous glomerulonephritis in terms of clinical
morphology [24, 25]. This experimental work showed a
negative selection of Т-killer cells (cytotoxic lymphocytes)
associated with active development of autoimmune renal
pathology. Prednisolone (reference immunodepressant)
monotherapy demonstrated adequate efficacy regarding
immune and metabolic components of renal disease.
Nephroprotective effects of CAN have been identified in
the experimental Heymann autoimmune glomeruloneph-
ritis. The herbal monotherapy was shown to partially
normalize urodynamics, increase rate of glomerular filtra-
tion, mildly decrease blood creatinine, and significantly re-
duce the severity of leukocyturia due to anti-inflammatory
effects of the herbal medicinal product. Combining CAN
with the immunosuppressant prednisolone promotes
more positive pharmacodynamic effects on the immune
and renal systems of rats. Synergistic effects of “Prednisol-
one + CAN” combination were demonstrated in the en-
hanced reduction of hematuria and leukocyturia, reduced
level of uremic toxins (products of deep protein oxidation
and carbonyl proteins) and blood cryoglobulins, and also
increased CD8 + −lymphocyte count.
Analysis of the resulting data indicates an increase
in effectiveness when treating glomerulonephritis with
a combination of immunosuppressive drugs with
herbal medicines. The combined treatment may be
useful in clinical nephrology practice including pa-
tients with kidney autoimmune diseases and should be
investigated further.
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Table 2 Effect of therapy with prednisolone, CAN and their combination on biochemical blood parameters in autoimmune
glomerulonephritis (mean ± SEM, n = 8 in each group)
Groups of animals Study parameters
BUN, mmol/L Creatinine, μmol/L Cholesterol, mmol/L AOPP, μmol/L РСО, nmol/mg
Healthy 4,3 ± 0,2 50,4 ± 3,5 1,22 ± 0,08 58,0 ± 10,1 0,79 ± 0,12
AIG 9,3 ± 0,6* 168,4 ± 11,9* 2,59 ± 0,17* 238,1 ± 13,1* 3,84 ± 0,31*
AIG + Prednisolone 6,4 ± 0,5*/† 101,3 ± 10,8*/† 1,97 ± 0,15*/† 154,6 ± 11,0*/† 2,59 ± 0,18*/†
AIG + CAN 8,6 ± 0,8*# 118,1 ± 9,3*/† 2,39 ± 0,23* 204,0 ± 20,3*/# 3,38 ± 0,17*/#
AIG + Prednisolone + CAN 5,3 ± 0,4*/† 86,2 ± 6,1*/† 1,72 ± 0,11*/† 105,7 ± 11,98*/†/# 1,99 ± 0,11*/†/#
* -differences are significant vs, healthy rats, р ≤ 0,05
† −differences are significant vs, AIG group, р ≤ 0,05
# -differences are significant vs, Prednisolone group, p ≤ 0,05
Table 3 Effect of therapy with prednisolone, CAN and their combination on renal function in autoimmune glomerulonephritis
(mean ± SEM, n = 8 in each group)
Groups of animals Study parameters
Diuresis, mL/day GFR, mL/min Protein, g/mmol Cr Erythrocytes, ×103/mL Leukocytes, ×103/mL Casts, units/mL
Healthy 13,3 ± 0,6 4,50 ± 0,32 0,13 ± 0,01 1,87 ± 0,69 7,6 ± 1,3 10,0 ± 4,2
AIG 5,6 ± 0,5* 0,63 ± 0,13* 1,05 ± 0,14* 27,25 ± 5,47* 324,4 ± 50,6* 102,5 ± 25,9 *
AIG + Prednisolone 10,5 ± 0,9*/† 2,98 ± 0,45*/† 0,43 ± 0,03*/† 9,25 ± 1,25*/† 197,0 ± 29,.2*/† 23,6 ± 3,2†
AIG + CAN 9,7 ± 0,9*/† 1,37 ± 0,14*/†/# 0,70 ± 0,05*/# 15,12 ± 0,79*/# 149,5 ± 46,6*/† 48,2 ± 5,3*/#
AIG + Prednisolone + CAN 12,5 ± 1,1† 3,24 ± 0,23*/† 0,29 ± 0,05*/† 5,00 ± 0,75*/†/# 82,6 ± 7,7*/†/# 19,0 ± 3,8†
* -differences are significant vs. healthy rats, р ≤ 0,05
† −differences are significant vs. AIG group, р ≤ 0,05
# -differences are significant vs. Prednisolone group, p ≤ 0,05
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